Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales figures.
What to Know: On Tuesday, Aurinia reported its full-year and fourth-quarter sales and earnings figures for the period that ended Dec. 31, 2022. The company also reaffirmed its full-year 2023 guidance.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The company announced a fourth-quarter loss of $0.18 per share compared to analyst estimates for a loss of $0.27 per share, representing a positive earnings surprise of 33.3%. Aurinia reported fourth-quarter sales of $28.43 million beating analyst estimates of $27.78 million.
Aurinia reported full-year 2022 revenues of $134 million, compared to $45.6 million in 2021.
Aurinia also provided guidance for 2023. The company expects double-digit revenue growth compared to 2022. Aurinia sees revenues from its drug, LUPKYNIS in the range of $120 million-$140 million.
"As an organization, we continue to advocate for improved screening, diagnosis and the treatment of lupus nephritis with healthcare providers while reinforcing the clinical benefits of LUPKYNIS over the historic standard of care," said Peter Greenleaf, president and CEO of Aurini a Pharmaceuticals.
See Also: Why Cardio Diagnostics Stock is Soaring Today
Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by autoimmune, kidney and rare diseases with a high unmet medical need.
According to data from Benzinga Pro, Aurinia Pharmaceuticals shares were up 9.66%, trading at $9.14 at the time of publication. The stock has a 52-week high of $16.30 and a 52-week low of $4.07.
Photo: courtesy of Aurinia.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.